ClinicalTrials.gg
Not yet recruitingNCT07885956Updated Oct 21, 2026

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults

A Phase 3 interventional study of RSVpreF (Regimen A) and RSVpreF (Regimen B) in Respiratory Syncytial Virus (RSV), sponsored by Pfizer. Not yet recruiting. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Updated Oct 21, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.

Read the detailed description

Respiratory syncytial virus (RSV) can cause serious respiratory illness in older adults. Previous studies showed that RSVpreF helped protect adults from RSV disease. This study will evaluate the safety of receiving another RSVpreF vaccination about 5 years after an earlier RSVpreF dose.

Participants who previously received RSVpreF in Study C3671013 will be assigned to one of three groups:

  1. receive a dose RSVpreF revaccination,
  2. receive a dose RSVpreF revaccination, or
  3. not receive revaccination and continue follow-up.

Researchers will evaluate side effects after vaccination and collect blood samples over approximately 18 months.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Must have participated in the previous Pfizer RSVpreF efficacy study (C3671013) and have been ≥60 years of age at the time of their enrollment in that study.
  • Must have received their initial RSVpreF dose in the C3671013 study about 5 years prior to enrollment in the current study (C3671087).
  • Must be determined to be in good health by the investigator, based on medical history and clinical judgment. Participants with stable chronic diseases (e.g., disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment) are eligible.

Key Exclusion Criteria:

  • History of a severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention or any related vaccine.
  • History of Guillain-Barré Syndrome of any subtype or etiology.
  • Certain serious or unstable medical conditions that could increase the risks of study participation.
  • Previous vaccination with any other or licensed RSV vaccine since receiving the initial dose in the C3671013 study.
  • Any medical or psychiatric condition that, in the investigator's judgment, would make the participant inappropriate for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    Group 1

    Participants will receive a single open-label, intramuscular injection of RSVpreF (Regimen A) as a revaccination.

    Biological: RSVpreF (Regimen A)

  • Experimental
    Group 2

    Participants will receive a single open-label, intramuscular injection of RSVpreF (Regimen B) as a revaccination.

    Biological: RSVpreF (Regimen B)

  • No intervention
    Group 3

    Participants will not be revaccinated.

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting local reactions

    Time frame: For up to 7 days after vaccination

  2. Percentage of participants reporting systemic events

    Time frame: For up to 7 days after vaccination

  3. Percentage of participants reporting adverse events

    Time frame: Through 1 month after vaccination

  4. Percentage of participants reporting newly diagnosed chronic medical conditions

    Time frame: Through 18 months after vaccination

  5. Percentage of participants reporting serious adverse events

    Time frame: Through 18 months after vaccination

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Feb 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 21, 2026
StartEst.
Oct 29, 2026
Primary completionEst.
Feb 7, 2029
CompletionEst.
Feb 7, 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07885956
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Oct 29, 2026 (estimated)
Primary completion
Feb 7, 2029 (estimated)
Completion
Feb 7, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regimen B

Start the discussion